Faron's BEXMAB Phase 1/2 study abstract has been accepted as a poster presentation at EHA 2026 Congress in Stockholm, Sweden (June 11-14, 2026)
The presentation will showcase translational insights and clinical efficacy of bexmarilimab combined with azacitidine in higher-risk MDS
Clinical data demonstrates 45% complete remission rate in treatment-naïve HR-MDS and 14.5-month median overall survival in relapsed/refractory MDS settings, surpassing historical azacitidine monotherapy benchmarks
The poster presentation is scheduled for Friday, June 12 at 18:45-19:
45 CEST
Faron will host a follow-up live webcast on June 15, 2026, featuring Dr. Mika Kontro, Principal Investigator and presenting author, with Q&A session
The data will detail the mechanism of action of bexmarilimab, including treatment-induced immune cell changes in the bone marrow and effects on malignant blasts
Faron is collaborating with City of Hope to develop a Phase II investigator-initiated trial of bexmarilimab in relapsed/refractory MDS, with first participant enrollment expected in H2 2026